INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Neumora Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NMRA
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Neumora Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NMRA |
| [25-February-2025] |
NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora" or the "Company") (NASDAQ: NMRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether Neumora and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until April 7, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Neumora securities during the Class Period. A copy of the Complaint can be obtained atwww.pomerantzlaw.com. [Click here for information about joining the class action] On or around September 15, 2023, Neumora conducted its initial public offering ("IPO"), selling 14.71 million shares of common stock priced at $17.00 per share. Then, on January 2, 2025, Neumora issued a press release announcing the results from the KOASTAL-1 study of Navacaprant for the treatment of moderate to severe major depressive disorder. The press release revealed that the KOASTAL-1 study failed to "demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale ('MADRS') total score at Week 6 or the key secondary endpoint of a change from baseline in the Snaith-Hamilton Pleasure Scale ('SHAPS') scale." In that same press release, Executive Vice President ("EVP") Rob Lenz stated that "[w]e are disappointed by the results from KOASTAL-1 as they were not consistent with the body of evidence supporting this mechanism." EVP Lenz also noted that there "is a lot to investigate from this study" due to the "contrast in drug and placebo responses in depressed mood and anhedonia in female compared to male participants." Following this news, Neumora's stock price fell $8.63 per share, or 81.42%, to close at $1.97 per share on January 2, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:
SOURCE Pomerantz LLP | ||
Company Codes: NASDAQ-NMS:NMRA |
View original content to download multimedia:
